medwireNews : The indication for the Janus kinase (JAK) inhibitor upadacitinib will be expanded to include nonradiographic axial spondyloarthritis (axSpA) in Europe, following a recommendation for approval by the EMA’s Committee for Medicinal Products for Human Use.

Findings from the SELECT-AXIS 2 trial provide further support for the benefits of upadacitinib across the spectrum of axial spondyloarthritis.

Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.

medwireNews : The National Institute for Health and Care Excellence has recommended upadacitinib as a treatment option for certain patients with active psoriatic arthritis (PsA) in England and Wales.

Upadacitinib may also be given to adult patients with AS and an inadequate response to conventional therapy.

medwireNews : The US FDA has approved upadacitinib for the treatment of adult patients with active psoriatic arthritis (PsA) and an inadequate response or intolerance to at least one tumor necrosis factor (TNF) inhibitor.

Upadacitinib has similar efficacy and safety profiles in patients with psoriatic arthritis regardless of whether the drug is administered as monotherapy or as an add-on treatment to conventional DMARDs, suggests a pooled analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials.

Individuals with rheumatoid arthritis receiving the oral Janus kinase inhibitor upadacitinib have higher rates of herpes zoster than those being treated with methotrexate alone or in combination with adalimumab, research shows.

Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, is a new treatment for RA.

A pooled analysis of data from the SELECT-PsA-1 and SELECT-PsA-2 trials suggests that treatment with the JAK inhibitor upadacitinib improves axial symptoms in patients with psoriatic spondylitis.

Author : Claire Barnard With upadacitinib now approved for psoriatic arthritis (PsA) in  Europe  and under consideration by the US FDA, we round up the key safety data on the Janus kinase (JAK)-1 selective inhibitor from the phase 3 studies, SELECT-PsA 1 and SELECT-PsA 2 .

The SELECT-PsA-1 and SELECT-PsA-2 trials presented at the EULAR 2020 E-Congress have demonstrated that upadacitinib may be a promising treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents.

Findings from the phase II/III SELECT-AXIS 1 trial suggest that treatment with upadacitinib may improve disease activity, function, and axial inflammation among biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to NSAIDs.

A pooled analysis of data from the SELECT trials suggests that the selective JAK1 inhibitor upadacitinib is not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism among patients with rheumatoid arthritis.

Treatment with the JAK inhibitor upadacitinib leads to significantly better clinical and radiographic outcomes than methotrexate therapy among patients with moderate-to-severe rheumatoid arthritis who have no or limited prior methotrexate exposure, show the SELECT-EARLY results.

Treatment with the JAK inhibitor upadacitinib leads to significantly better clinical and radiographic outcomes than methotrexate therapy among patients with moderate-to-severe rheumatoid arthritis who have no or limited prior methotrexate exposure, show the SELECT-EARLY results.

The JAK1 selective inhibitor upadacitinib improves disease activity to a greater degree than abatacept in rheumatoid arthritis patients with previous biologic exposure, show data presented at the EULAR 2020 E-Congress.

This announcement follows approval of upadacitinib for RA by the US FDA in August 2019.

Click here for a guide to the SELECT trials of upadacitinib in patients with RA   Upadacitinib will be available as extended-release tablets and is recommended at a dose of 15 mg orally once daily.